SAN ANTONIO — Tirzepatide demonstrated long-term weight-loss benefits and prevention of diabetes progression in patients with obesity and prediabetes, but only so long as they continued the ...

Tirzepatide, a once-weekly dual agonist, outperforms long-acting insulin in reducing HbA1c, body weight, and improving cardiovascular markers in Type 2 diabetes patients.

Tirzepatide confers significant weight loss and cardiometabolic benefits for patients with diabetes and overweight or obesity, especially for those who lose more weight earlier during treatment, a ...

GLP-1 receptor agonists like semaglutide have demonstrated benefits in slowing the progression of kidney disease in patients with diabetes. Tirzepatide may have similar advantages. Semaglutide vs ...

Metabolic hypogonadism, a condition marked by low testosterone levels and frequently seen in obese individuals, contributes ...

GLP-1RA users had a 37% lower risk of developing dementia compared to those on other antidiabetic drugs. Stroke risk reduced ...

Glucagon-like peptide 1 receptor agonists may offer neuroprotective and survival benefits beyond blood sugar control.

Weight-loss injections, including popular drugs like Wegovy and Mounjaro, may offer a protective shield against serious ...

In patients with type 2 diabetes (T2D), tirzepatide is associated with a reduced risk for all-cause mortality, major adverse cardiovascular events (MACEs), major adverse kidney events, and acute ...

Tirzepatide helps obese adults lose over 15% of body weight in 52 weeks—and retain much of it even six months after stopping ...

Tirzepatide benefits people with obesity, kidney disease and heart failure. Story by Science X staff ... as well as for treating Type 2 diabetes through its impact on blood sugar levels. ...

Mounjaro is the brand name for tirzepatide, ... Here are the key benefits of Mounjaro: 1. Manages diabetes. It helps in managing type 2 diabetes by increasing the production of insulin in the body.